Mancuso Laura A, Nadelstein Brad, Berdoulay Andrew, Spatola Ronald A
Animal Eye Care, Virginia Beach, Virginia.
Animal Eye Care, Chesapeake, Virginia.
Vet Ophthalmol. 2019 Jul;22(4):477-484. doi: 10.1111/vop.12616. Epub 2019 Feb 18.
To evaluate the postoperative effect of intracameral tPA (alteplase; Activase®, Genentech, San Francisco, CA), administered at immediate conclusion of phacoemulsification, on anterior chamber fibrin formation in dogs.
Forty-one dogs (82 eyes) undergoing bilateral phacoemulsification received 25 μg/0.1 mL intracameral tPA in one eye and 0.1 mL unmedicated aqueous vehicle in the contralateral eye immediately after corneal incision closure. Intraocular pressure (IOP) was measured, and severity of anterior chamber fibrin formation, aqueous flare, pigment precipitates on the intraocular lens (IOL) implant, posterior capsular opacification (PCO), and corneal edema were graded at approximately 1 week, 2-3 weeks, 4-6 weeks, 8-12 weeks, and greater than 3 months postoperatively.
Anterior chamber fibrin developed postoperatively in 68.3% of dogs (28/41) and 50% of eyes (41/82). In tPA-treated eyes, 53.7% (22/41) developed fibrin compared to 46.3% of control eyes (19/41). Some degree of postoperative ocular hypertension (POH) occurred in 53.7% of dogs (22/41) and 36.5% of eyes (30/82). In tPA-treated eyes, 34.1% (14/41) experienced POH compared to 39% of control eyes (16/41). Additional intracameral tPA injection was later required in 29.3% of both tPA-treated (12/41) and control eyes (12/41).
Administration of intracameral tPA at immediate conclusion of canine phacoemulsification had no clinically observable effect on anterior chamber fibrin incidence at any time point. tPA-treated eyes showed no prophylaxis against POH or secondary glaucoma compared to control eyes and received late postoperative tPA injections at the same frequency as control eyes.
评估在白内障超声乳化术结束时立即前房内注射组织型纤溶酶原激活剂(阿替普酶;Activase®,基因泰克公司,加利福尼亚州旧金山)对犬眼前房纤维蛋白形成的术后效果。
41只接受双侧白内障超声乳化术的犬(82只眼)在角膜切口闭合后,一只眼接受25μg/0.1mL前房内注射阿替普酶,对侧眼注射0.1mL未加药物的房水载体。测量眼内压(IOP),并在术后约1周、2 - 3周、4 - 6周、8 - 12周及术后3个月以上对眼前房纤维蛋白形成的严重程度、房水闪光、人工晶状体(IOL)植入物上的色素沉着、后囊膜混浊(PCO)和角膜水肿进行分级。
术后68.3%的犬(28/41)和50%的眼(41/82)出现前房纤维蛋白。在接受阿替普酶治疗的眼中,53.7%(22/41)出现纤维蛋白,而对照眼中为46.3%(19/41)。53.7%的犬(22/41)和36.5%的眼(30/82)出现某种程度的术后高眼压(POH)。在接受阿替普酶治疗的眼中,34.1%(14/41)出现POH,而对照眼中为39%(16/41)。之后,29.3%接受阿替普酶治疗的眼(12/41)和对照眼(12/41)都需要额外进行前房内阿替普酶注射。
在犬白内障超声乳化术结束时立即前房内注射阿替普酶,在任何时间点对眼前房纤维蛋白发生率均无临床可观察到的影响。与对照眼相比,接受阿替普酶治疗的眼对POH或继发性青光眼无预防作用,且术后晚期接受阿替普酶注射的频率与对照眼相同。